TSPO Antibody

What is TSPO and why is it significant in research?

TSPO (Translocator Protein 18 kDa) is a protein predominantly located in the outer mitochondrial membrane that plays crucial roles in steroidogenesis, mitochondrial function, metabolism, cell proliferation, and apoptosis. It has gained significant research interest due to its upregulation in various pathological conditions, particularly neuroinflammation and brain tumors. TSPO is most abundant in steroid-synthesizing tissues (adrenal and gonadal), with intermediate expression in heart and kidney, and lower levels in liver and brain . Its expression increases dramatically in activated microglia during brain injury or pathology, making it an important biomarker for neuroinflammation .

What are the cellular sources of TSPO expression in healthy versus diseased brain tissue?

In healthy brain tissue, TSPO is primarily expressed in mitotic cells including vascular endothelial cells, ependymal cells, and neural stem cells, consistent with its function in mitochondrial energetics . In contrast, TSPO expression dramatically increases in disease states, particularly in activated (but not resting) microglia during nerve injury or brain pathologies . This differential expression pattern makes TSPO a valuable marker for tracking neuroinflammation. Studies comparing TSPO distribution between rodents and humans show similar patterns, with expression levels varying by tissue type rather than strictly correlating with mitochondrial content .

How do I properly handle and store TSPO antibodies for optimal results?

For optimal results with TSPO antibodies in research applications, proper storage and handling are critical. Based on product information, TSPO antibodies should typically be stored according to manufacturer recommendations. For the specific TSPO antibody referenced in the search results, western blotting applications require a 1:1000 dilution . Always check reactivity - the referenced antibody shows reactivity with human, mouse, and monkey species . When working with TSPO antibodies, it's important to validate specificity through appropriate controls, especially considering the ongoing debates about TSPO functions in different experimental models.

What are the recommended applications for TSPO antibodies in neuroscience research?

TSPO antibodies serve as valuable tools in neuroscience research, primarily for:

• Western blotting: Used to quantify TSPO expression levels in brain tissue samples with recommended dilutions of 1:1000

• Neuroinflammation studies: To track microglial activation in various CNS pathologies and psychiatric disorders

• Comparative analysis: To examine TSPO expression across different brain regions, cell types, and disease states

• Validation of TSPO-targeting therapies: To confirm target engagement in therapeutic development studies

• Correlation studies: To validate in vivo PET imaging findings with ex vivo tissue analysis

TSPO antibodies are particularly valuable when combined with other microglial and inflammatory markers to provide a comprehensive assessment of neuroinflammatory processes.

How does TSPO expression correlate with immune cell infiltration in CNS tumors and what are the methodological considerations?

Recent research demonstrates a complex relationship between TSPO expression and immune cell infiltration in CNS tumors, particularly glioblastoma (GB). Studies show that TSPO transcription in primary GB cells correlates positively with CD8+ T cell infiltration, cytotoxic activity of T cell infiltrate, expression of TNFR and IFNGR, and activity of their downstream signaling pathways .

Methodologically, this correlation can be studied through:

• Genetic manipulation of TSPO expression in brain tumor initiating cells (BTICs) and cell lines

• Co-culture experiments with antigen-specific cytotoxic T cells and autologous tumor-infiltrating T cells

• Analysis of death-inducing intrinsic and extrinsic apoptotic pathways affected by TSPO

• Gene expression analysis to identify TSPO-regulated genes mediating apoptosis resistance

Importantly, research has revealed that TSPO expression in GB is induced through T cell-derived cytokines TNFα and IFNγ, and that TSPO expression protects GB cells against cytotoxic T cell attack through TRAIL . This suggests potential methodological approaches focusing on TSPO as a therapeutic target to sensitize GB to immune cell-mediated cytotoxicity by circumventing tumor intrinsic TRAIL resistance.

What are the current contradictions in TSPO knockout studies and how can they be reconciled in experimental design?

Current literature reveals significant contradictions in TSPO knockout studies, particularly regarding its role in steroidogenesis. These contradictions stem from different experimental approaches and genetic models:

• Contradictory findings:

  • Some studies report no effect of TSPO knockdown on progesterone production in MA-10 cells 48 hours after siRNA transfection

  • In contrast, earlier studies using antisense oligodeoxynucleotides or antisense knockdown showed significant reduction in steroid production in the same cell line

  • Studies using CRISPR/Cas9 technology to generate Tspo KO MA-10 cell lines yielded conflicting results, with some reporting that PK 11195 (TSPO ligand) stimulation still affected steroidogenesis

• Methodological reconciliation approaches:

  • Verification of complete TSPO deletion through binding assays (absent in some studies)

  • Consideration of ligand concentration (nanomolar versus micromolar) as high concentrations may have non-specific effects

  • Evaluation of genetic linkage issues (e.g., the Tspo and Amhr2-Cre genetic linkage with 18.1 cM genetic distance that complicated tissue-specific knockout attempts)

  • Assessment of early embryonic lethality/adverse effects that may mask phenotypes

These contradictions highlight the importance of comprehensive experimental design that includes verification of knockout efficiency, appropriate controls, and consideration of developmental timing when targeting TSPO.

How does the specificity and sensitivity of TSPO antibodies compare across different neuroinflammatory conditions and what validation steps are crucial?

The specificity and sensitivity of TSPO antibodies vary across neuroinflammatory conditions, requiring careful validation:

• Specificity considerations:

  • TSPO expression increases in activated microglia but remains low in resting microglia

  • Expression patterns differ between acute versus chronic neuroinflammation

  • Different brain regions show varying baseline and induced TSPO expression levels

  • TSPO is expressed in multiple cell types including microglia, astrocytes, vascular endothelial cells, ependymal cells, and neural stem cells

• Essential validation steps:

  • Correlation with established microglial/macrophage markers (e.g., ED-1) and astrocyte markers (e.g., GFAP)

  • Use of knockout controls to confirm antibody specificity

  • Multi-method verification (e.g., combining western blotting, immunohistochemistry, and flow cytometry)

  • Species-specific validation (antibody may show different reactivity patterns across species)

  • Assessment of cross-reactivity with other mitochondrial proteins

Research shows varying correlations between TSPO binding and specific cell types. For example, in traumatic brain injury models, increased [³H]PK11195 binding (a TSPO ligand) correlated with both ED-1-positive cells (microglia/macrophages) and GFAP-positive astrocytes, though the correlation was stronger with ED-1 .

What molecular mechanisms underlie TSPO-mediated protection against apoptosis and how can this be experimentally evaluated?

TSPO plays a complex role in regulating apoptosis through several molecular mechanisms:

• Key molecular mechanisms:

  • TSPO selectively protects brain tumor initiating cells (BTICs) against TRAIL-induced apoptosis by regulating apoptotic pathways

  • TSPO regulates the expression of multiple genes associated with resistance against apoptosis

  • TSPO interacts with NOX enzymes and affects downstream signaling pathways including NF-kB, AP-1, and the MAPK pathway

  • TSPO is involved in modulating reactive oxygen species (ROS) formation in response to various stress stimuli

• Experimental evaluation approaches:

  • Genetic manipulation of TSPO expression followed by assessment of susceptibility to apoptotic stimuli

  • Measurement of caspase 3, 8, and 9 levels in response to TSPO modulation

  • Analysis of mitochondrial membrane potential (ΔΨm) depolarization

  • ADP/ATP ratio determination to assess mitochondrial function

  • Assessment of oxidative stress levels in response to TSPO targeting

  • Quantification of apoptosis through Hoechst staining and Fluorescence Activated Cell Sorting (FACS) assays

Research has demonstrated that silencing TSPO sensitizes BTICs against T cell-mediated cytotoxicity, suggesting TSPO as a potential therapeutic target for enhancing immune-mediated tumor cell killing .

How can TSPO ligands be optimized for therapeutic applications in neuroinflammatory and neurodegenerative diseases?

The optimization of TSPO ligands for therapeutic applications requires careful consideration of several factors:

• Ligand specificity and efficacy:

  • Develop ligands with high specificity for TSPO to avoid off-target effects

  • Consider the structure-activity relationship of various ligand classes (e.g., N,N-dialkyl-2-arylindol-3-ylglyoxylamides or PIGAs)

  • Evaluate the ability of ligands to modulate inflammatory and apoptotic processes at nanomolar concentrations

• Mechanism of action considerations:

  • Determine whether therapeutic effects depend on neurosteroid synthesis (e.g., pregnenolone) as suggested by studies showing reduced protective effects of PIGAs when co-treated with the pregnenolone synthesis inhibitor SU-10603

  • Assess the impact on inflammatory mediator production (e.g., TNF-α expression and secretion, ROS production)

  • Evaluate effects on microglial proliferation and activation state

• Delivery and targeting strategies:

  • Optimize blood-brain barrier penetration for CNS applications

  • Consider cell-specific targeting to affect particular TSPO-expressing cell populations

  • Evaluate combination approaches with other anti-inflammatory or neuroprotective agents

TSPO ligands have shown promise in reducing LPS-driven cellular cytotoxicity and modulating inflammatory and apoptotic processes in cellular models , suggesting their potential utility in inflammatory-based retinal neurodegeneration and other CNS pathologies.

TSPO Antibody Specifications and Applications

Table 1: Key specifications of TSPO antibody relevant for research applications

TSPO Expression Across Tissues and Disease States

Table 2: Differential TSPO expression across tissues and disease conditions

TSPO-Mediated Cellular Processes in Health and Disease

Table 3: TSPO functions in various cellular processes with supporting experimental evidence